Skip to main content
. Author manuscript; available in PMC: 2012 Aug 14.
Published in final edited form as: J Addict Res Ther. 2011 Dec 24;Suppl 4:007. doi: 10.4172/2155-6105.S4-007

Figure 1.

Figure 1

Depicts locomotor activity (indicated by ambulations/10 min as recorded by the Comprehensive Lab Animal Monitoring System) of mice (n = 8/group) administered intraperitoneal (i.p.) saline or (A) the kappa opioid receptor agonist, U50,488 (0.3, 1.0, or 10.0 mg/kg) or (B) the peripherally-restricted kappa opioid receptor agonist, ffir-NH2 (3 nmol, i.c.v., 10 nmol, i.c.v., 1 mg/kg, i.p., or 10 mg/kg, i.p.). *denotes an interaction wherein the indicated group significantly differs from the respective saline-administered control group (p < 0.05).